Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Illumina Launches BaseSpace® Apps

Published: Friday, May 17, 2013
Last Updated: Friday, May 17, 2013
Bookmark and Share
Beta phase ends, platform enables E-commerce for developers with introduction of iCredits™.

Illumina, Inc. has announced the full commercial availability of BaseSpace, the Company's genomics cloud computing and storage platform.

BaseSpace Apps is now out of beta status, and includes a full-fledged e-commerce system that allows customers to quickly and easily purchase Illumina and third-party bioinformatics applications (apps).

BaseSpace e-commerce transactions are based on BaseSpace iCredits, a medium of exchange that can be purchased and spent within BaseSpace.

BaseSpace has rapidly become a valuable platform for bioinformatics app developers. During the beta period, users launched individual BaseSpace apps more than 4,000 times.

Now, with BaseSpace iCredits, developers can easily add e-commerce functionality to their apps, leveraging Illumina's complete payment solution.

"The commercial availability of BaseSpace Apps is an important milestone for both Illumina customers and BaseSpace app developers. For customers, BaseSpace has transitioned into a fully-supported bioinformatics platform; for BaseSpace app developers, BaseSpace now has a comprehensive e-commerce capability that enables them to monetize their efforts," said Alex Dickinson, Illumina's Senior Vice President, Cloud Genomics.

Dickinson continued, "With rapid adoption of BaseSpace by users of Illumina's high-throughput HiSeq® next-generation sequencing systems, and the continued use of the platform by users of Illumina's MiSeq® desktop sequencing systems, the scale of growth potential for BaseSpace Apps is increasing exponentially."

"BaseSpace continues to attract a large number of app developers who can rapidly make their bioinformatics tools available to thousands of Illumina customers," added Jordan Stockton, Illumina's Director of Product Marketing, Computational Biology.

Stockton continued, "BaseSpace is designed to support apps that enable genomics research in diverse markets including cancer, microbiology, and genetic disease."

Through the BaseSpace ecosystem, a diverse collection of new apps are now available for Illumina's MiSeq and HiSeq systems. For example, Elsevier Publishing, the world's leading publisher of scientific and health information, has released a BaseSpace app that enables users to submit data directly into the peer-review publication process.

"We're excited to be working with Illumina to accelerate the scientific publication process," said Bart Wacek, Executive Publisher, Elsevier Life Sciences.

Wacek continued, "Through BaseSpace, scientists can directly submit their data and manuscript to our Genomics Data journal, allowing the data review to be an integral part of the peer-review process."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Illumina Invests In New Venture Fund
Illumina will commit $100M over 10 years to drive genomic technology development.
Friday, April 15, 2016
Illumina Sues Oxford Nanopore for Patent Infringement
Illumina, Inc. has announced that the company filed lawsuits against Oxford Nanopore Technologies Ltd. and Oxford Nanopore Technologies, Inc. (ONT).
Wednesday, February 24, 2016
Illumina Signs Multiple Biobank Deals
MEGA array family and next-generation sequencing to support comprehensive genomics approach toward personalized medicine.
Wednesday, February 03, 2016
Illumina Acquires Conexio Genomics
Acquisition strengthens company’s ability to deliver sample-to-report solutions for HLA typing.
Wednesday, January 27, 2016
Illumina Forms New Company
GRAIL to enable early cancer detection via blood-based screening.
Tuesday, January 12, 2016
Bio-Rad, Illumina Partner
Scalable, high-throughput platform to offer unprecedented insight into gene expression of individual cells.
Tuesday, January 12, 2016
Novogene and Illumina Enters into Agreement
Agreement to co-develop NGS diagnostic system for reproductive health and oncology applications.
Wednesday, December 16, 2015
bioMérieux and Illumina Announce the Launch of bioMérieux EpiSeq™
A revolutionary next-generation sequencing service for epidemiological monitoring of bacterial infections.
Tuesday, December 15, 2015
Illumina Accelerator Announces Third Funding Cycle of Genomics Startups
Invests in synthetic biology, reproductive health, skin microbiome and nutrition startups.
Thursday, December 10, 2015
Desktop Genetics Receives Strategic Investment from Illumina
Illumina invests in Desktop Genetics' technology to support the platform's integration with NGS pipelines and improve CRISPR genome editing workflows.
Thursday, December 10, 2015
Amoy Diagnostics and Illumina Enter Strategic Collaboration
Collaboration for next-generation sequencing cancer diagnostics in China.
Thursday, October 01, 2015
Illumina Joins WIN Consortium in Personalized Cancer Medicine
A global network of leading academic, industry, insurance and non-profit research organizations.
Thursday, September 24, 2015
MSK and Illumina Launch Comprehensive Circulating Tumor DNA Program
Collaboration aims to determine range of opportunities for non-invasive cancer diagnosis and monitoring.
Thursday, September 17, 2015
Illumina Completes Acquisition of GenoLogics
Illumina’s to drive the adoption of sequencing in new markets and improve the genomic workflow.
Wednesday, September 02, 2015
Burning Rock and Illumina Collaborate on Molecular Diagnostics for Oncology
Collaboration highlights the ever-increasing importance of genomics to improve healthcare in China.
Tuesday, August 25, 2015
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Cancer Related Immune Response Genes Uncovered
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer.
Deciphering Inactive X Chromosomes
Untangling the Barr body of inactive X chromosomes valuable for understanding chromosome structure and gene expression.
Micro Disease-Detecting Sensor Created
Researchers at McMaster University have created a microscopic disease-detecting sensor that can turn on to detect trace amounts of substances.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!